Where others have failed will Atl1102 succeed ?, page-419

First 419 Last

Share
Profile

Follow
itsagas

13,427 Posts.

1439

29/09/21

17:31

Post #: 56441373
Share

Originally posted by samfiodiving: ↑

If there was going to be rejection it would have been done on the initial feedback

Ref
ANP through its interactions with PDCO, is looking to ensure that its planned clinical studies will be run in accordance with PDCO expectations for future product approval.Nuket Desem, Director, Clinical and Regulatory Affairs at Antisense Therapeutics said: “The EMA’s PDCO feedback via the PIP Summary Report was constructive. We have appreciated the collaborative approach of the EMA to assist us in refining the study design for the proposed Phase IIb clinical trial in Europe

IMHO

They will have refined the trial to support the advice from the PIP summary

Just a formality from what i can see but these are the timelines and these are the hoops we have to jump through

I Have no concerns with this

What i do have concerns over however is

Yes we know the science is good infact it's overly good, it's fantastic in the field we are in so will not question this area

I am sincerely hoping my scenario of 50% world exposure to a pharma comes to fruition and you will not hear a word from me except to congratulate the board if the deal lives up to expectations they have put out there

BUT

If we are to go down the CR route then one has to seriously ask the question,

For all that has been achieved over this past year and we are left to go it alone,

Then why has there been no effort to achieve investment in the market to drive our SP, because let's face it for all we have achieved

There is no major interest in the market for ANP we are basically illiquid and would be if it was not for the Botman of the stock, we are not allowed to go down but on the same footing we are not allowed to go up

WHY

Have not even touched resistance yet that we have to push through between 23c & 24.5c

I am hoping this is a sign of scenario one and we don't need it because of what could well be coming

See how we go

Expand

Good post Sam

ANP Price at posting: 19.8¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 678 more messages in this thread...

First 419 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 10.5¢		Change 0.000(0.00%)		Mkt cap ! $94.66M

Open	High	Low	Value	Volume
10.5¢	10.5¢	10.5¢	$21.40K	203.8K

Buyers (Bids)

No.	Vol.	Price($)
4	215964	10.0¢

Sellers (Offers)

Price($)	Vol.	No.
10.5¢	341886	4

View Market Depth

No.	Vol.	Price($)
4	215964	0.100
1	100000	0.099
2	108491	0.098
2	41236	0.097
1	10004	0.096

Price($)	Vol.	No.
0.105	341886	4
0.110	258011	4
0.115	631198	7
0.120	381142	9
0.125	110429	2

Last trade - 10.06am 07/10/2024 (20 minute delay)

PER (ASX) Chart

Where others have failed will Atl1102 succeed ?, page-419

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Where others have failed will Atl1102 succeed ?, page-419

Top Stories

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News